CITY OF INDUSTRY, Calif., Feb. 28, 2005 (PRIMEZONE) -- U.S. BioDefense (OTCBB:UBDE) is pleased to announce that has launched T2X.us, "The #1 High Tech Transfer Search Engine", which is developing a search engine identifying intellectual property modeling the successful business model functionality of search engines like Google (Nasdaq:GOOG), Yahoo (Nasdaq:YHOO), and LookSmart (Nasdaq:LOOK). U.S. BioDefense staff currently uses the search engine to accelerate the identification of stem cell and biodefense intellectual property acquisition programs. Programmers are now updating its T2X search engine for more robustness in preparation for a commercial version launch.
T2X is a search engine facilitating innovation exchange connecting VC's, small business, and public companies seeking technologies with universities, government agencies, and scientists. Over $30 billion is invested in innovation each year and much of the new technology developed is never put to commercial use. T2X is an online Technology Transfer Exchange where commercial members can identify technology that is available for licensing or partnering from universities, research labs, and scientists.
Numerous tools are available on T2X.us including an abstract research for technology at the National Institutes of Health and the functionality to search for technology available for licensing. Searchable technologies consist of vaccines, drug discovery, nano technology and general biology from sources such as the U.S. Patent and Trademark Office, Harvard's Office for Technology Transfer, University of California at Irvine Office of Technology Alliances, National Aeronautics and Space Administration (NASA), Small Business Administration, and the Environmental Protection Agency (EPA).
The T2X search engine will also be integrated into U.S. BioDefense's Open Source Stem Cell Research and Development Platform, which promotes collaboration amongst researchers, scientists and industry experts in the field of stem cell technology. T2X's ability to help identify intellectual property will boost the functional value of the open source platform helping participants explore the full realm of possibilities for research and development.
About U.S. BioDefense, Inc.
U.S. BioDefense is a Department of Defense central contractor that researches, develops, and commercializes leading-edge biotechnology. For additional information about our company please visit our web site at usbiodefense.com .
Safe Harbor Statement Forward-Looking Statements
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the U.S. BioDefense's financial performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to the U.S. BioDefense's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Information with respect to important factors that should be considered is contained in the U.S. BioDefense's Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The U.S. BioDefense does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.